Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer
ConclusionThe detection of ctDNA is a sensitive and dynamic biomarker for disease recurrence in CRC. Many investigations are underway into ctDNA ’s potential role in surveillance and treatment algorithms, and it has the potential to become a critical biomarker to determine individualized strategies for treatment sequencing, choice, and duration of therapies.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | Gastroenterology | Liver | Urology & Nephrology